Theophylline
- 15 October 2013
- journal article
- review article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 188 (8), 901-906
- https://doi.org/10.1164/rccm.201302-0388pp
Abstract
Theophylline (dimethylxanthine) has been used to treat airway diseases for more than 80 years. It was originally used as a bronchodilator, but the relatively high doses required are associated with frequent side effects, so its use declined as inhaled β2-agonists became more widely used. More recently it has been shown to have antiinflammatory effects in asthma and chronic obstructive pulmonary disease (COPD) at lower concentrations. The molecular mechanism of bronchodilatation is inhibition of phosphodiesterase (PDE)3, but the antiinflammatory effect may be due to inhibition of PDE4 and histone deacetylase-2 activation, resulting in switching off of activated inflammatory genes. Through this mechanism, theophylline also reverses corticosteroid resistance, and this may be of particular value in severe asthma and COPD, wherein histone deacetylase-2 activity is reduced. Theophylline is given systemically (orally as slow-release preparations for chronic treatment and intravenously for acute exacerbations of asthma). Efficacy is related to blood concentrations, which are determined mainly by hepatic metabolism, which may be increased or decreased in several diseases and by concomitant drug therapy. Theophylline is now usually used as an add-on therapy in patients with asthma not well controlled on inhaled corticosteroids with or without long-acting β2-agonists and in patients with COPD with severe disease not controlled by bronchodilator therapy. Side effects are related to plasma concentrations and include nausea, vomiting, and headaches due to PDE inhibition and at higher concentrations to cardiac arrhythmias and seizures due to adenosine A1-receptor antagonism. In the future, low-dose theophylline may be useful in reversing corticosteroid resistance in COPD and severe asthma.Keywords
This publication has 48 references indexed in Scilit:
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Effect of theophylline on exercise capacity in COPD patients treated with combination long-acting bronchodilator therapy: a pilot studyInternational Journal of Chronic Obstructive Pulmonary Disease, 2012
- Targeting Phosphoinositide-3-Kinase-δ with Theophylline Reverses Corticosteroid Insensitivity in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary diseaseTrends in Pharmacological Sciences, 2009
- Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary diseaseBritish Journal of Pharmacology, 2009
- Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2Biochemical and Biophysical Research Communications, 2009
- Oxidative stress modulates theophylline effects on steroid responsivenessBiochemical and Biophysical Research Communications, 2008
- Global strategy for asthma management and prevention: GINA executive summaryEuropean Respiratory Journal, 2008
- Inhibition of reactive nitrogen species production in COPD airways: comparison of inhaled corticosteroid and oral theophyllineThorax, 2006
- Aminophylline Improves Diaphragmatic ContractilityThe New England Journal of Medicine, 1981